Du Pont Merck: Return to the Starting Gate
Executive Summary
Du Pont's acquisition of Merck's share of the company's pharmaceutical joint venture doesn't seem to put Du Pont in a position to address any of the problems the joint venture structure was supposed to solve--but obviously didn't. The acquisition may, in fact, be more of a response to Monsanto's aggressive moves in agriculture and its success with its GD Searle unit.